ArticleResuscitation plus2025
Use of Auto Transfusion Tourniquet increases end-tidal-CO
Article in Resuscitation plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06153160 ("The Effect of the Use of an Autotransfusion HemaShock Device on Hemodynamic Parameters During Resuscitation"), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"The Effect of the Use of an Autotransfusion HemaShock Device on Hemodynamic Parameters During Resuscitation"
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Out-of-hospital cardiac arrest (OHCA) remains a leading cause of mortality, with low survival rates despite advancements in cardiopulmonary resuscitation (CPR) and emergency care. This study aimed to evaluate the safety and effectiveness of the HemaShock® Auto-Transfusion Tourniquet (A-TT) in OHCA patients by assessing its impact on ACLS quality, ROSC rate and end-tidal CO Methods: This was a feasibility pilot study conducted in the pre-hospital setting of Maribor, Slovenia. The study was registered at ClinicalTrials.org #NCT06153160 and was approved by the Institutional Ethics Committee. Twenty-four OHCA patients were enrolled and divided into two groups: 12 patients received standard advanced cardiac life support (ACLS) plus A-TT (Study Group), while 12 received only ACLS (Control Group). The primary efficacy outcome was the difference in PetCO Results: There were no significant demographic differences between the two groups.. A-TT was successfully applied in 12 patients, with one case being ineffective. Return of spontaneous circulation (ROSC) was achieved in 50 % of the Study Group and 33 % of the Control Group (NS). PetCO Conclusions: The use of A-TT in OHCA patients did not interfere with ACLS protocols and did not reduce ROSC rate. The significant transient increase in PetCO Open science: The pilot study was registered into Clinical Trials in February 2023. The trial number is NCT06153160. The trial protocol can be assessed through the webpage cinicaltrials.gov.org.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.